

## **OVERVIEW**

We invite you to the first one of the 2021's Scientific Meetings and Conventions sponsored by the Puerto Rico's Hematology and Medical Oncology Association (AHOMPR). As the year 2020 came to an end trailing with it the challenges imposed by the COVID-19 pandemic, it also brought with it the need of overcome many of those hurdles with new and improved opportunities to bring the scientific community closer than ever.

The AHOMPR is not an exception, with our first virtual meeting, we bring the opportunity of first-class continuing medical education event for the diagnosis and treatment of patients who pertain to the Hematology and Medical Oncology subspecialty realm.

This Annual Meeting will provide you with the most updated research and with practical information for day to day care of your patients.

This year's program will bring together world-class and trend setters experts in matters of Hematology and Medical Oncology. You will have the chance to learn from and interact with experts from across the nation and from different continents in areas so diverse such as benign hematology, pediatric hematology and oncology, immunotherapy, biologic and targeted agents. All of it with a multidisciplinary approach in mind. By joining us, you will have the opportunity to learn updated and state-of-the-art care in such broad and exciting areas such as:

- Molecular testing in the new oncologic universe
- New therapeutic tools against oncogene-driven solid tumors
- Novel immunotherapy-based regimens
- The role of consolidation and maintenance immunotherapy
- Integration of surgery, radiation oncology, molecular dissection and immunotherapy in patients with diverse malignancies

We look forward to seeing you there!

Dr. Sixto Perez, M.D. President AHDMPR



### **TARGET AUDIENCE**

This educational activity is directed toward oncologists and hematologist involved in the treatment of patients with different types of cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment.

### **ACCREDITATION STATEMENT**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of "Academia Médica del Sur" and "(Asociacion de Hematologia y Oncologia Medica de Puerto Rico)."

The "Academia Médica del Sur" is accredited with Commendation by the ACCME to provide continuing medical education for physicians." The Academia Médica del Sur designates this live webinar presentation for a maximum of (21 ) AMA, PRA Category 1™ Credits.

Physicians should claim credits commensurate with the extent of their participation in the activity

For more information:

**Germaine Quiñones** 

Meeting Coordinator Tel: 787-608-1477

Fax: 787-841-6886

e-Mail: ahomprga@gmail.com







### **Learning Objectives**

At the conclusion of this activity, you should be better prepared to:

- Know the latest developments in the treatment of acute myelogenous leukemia and how to incorporate novel targeted therapies into practice.
- Consider advances in molecular markers to better inform screening, prognosis and treatment decision-making for patients with gastrointestinal cancers
- Increase knowledge of novel immunotherapies for gastrointestinal cancer, including appropriate patient selection and optimal treatment sequencing.
- Understand the impact COVID-19 has had on breast cancer patients and treatments
- Incorporate emerging clinical evidence for HER2-targeted agents into individualized treatment plans for patients with early-stage or advanced/metastatic HER2+ breast cancer
- Analyze recent data on the efficacy and safety of immunotherapy options for the treatment of patients with breast cancer
- Select appropriate diagnostic approach and treatment in amyloidosis.
- Assess clinical trial data of current and emerging agents and regimens that impact management strategies for
  patients with Relapsed/Refractory Hodakin lymphoma (HL)
- Assess clinical data concerning single-agent and combination immunotherapeutic approaches to manage non-meta static lung cancer
- Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC
- Evaluate safety and efficacy data regarding emerging treatment options and novel formulations in the management of MDS and integrate it into clinical scenarios
- Describe evidence-based strategies for risk stratification and risk-based management of SMM and discuss evolving
  options to optimize management strategies for patients with high-risk SMM
- Evaluate current clinical data and emerging approaches with CAR T-cell therapy for the management of patients with hematologic malignancies
- Discuss criteria for selection of patients for CAR T-cell therapy and best practices for referral and follow-up of patients from community practices
- Describe the major challenges in the clinical management of patients with cancer brought upon by the COVID-19 pandemic and outline clinical practice recommendations proposed by oncology societies regarding cancer care during the COVID-19 pandemic
- Recognize guideline recommendations regarding risk stratification, monitoring, and management strategies to mitigate cardiovascular risk in the oncology patient.
- Utilize risk stratification strategies to develop appropriate treatment plans for adult as well as pediatric patients with
- ALL based on cytogenetic and immunophenotype characteristics
- Detail strategies for first line and second-line management of patients living with AA and BM failure syndromes, as well as
  emerging options in the first line setting
- Recognize and understand molecular features of the five childhood brain tumors that present also in early adulthood and to learn the latest treatments for brain tumors shared by children and young adults.
- Address novel and emerging treatments of pediatric patients with bone and soft tissue sarcoma
- Explain efficacy and safety data supporting novel therapeutic modalities in SCD
- Increase knowledge in HSCT and deepen understanding of advanced topics in cellular therapies in pediatric patients





Paul A Meyers, MD
Professor of Pediatrics
Weill Cornell Medical College
Robbins Family Chair in Pediatrics
Vice Chair, Department of Pediatrics
Chief, Sarcoma Service
Memorial Sloan-Kettering Cancer Center
New York, NY 10065



Mariana Chavez MacGregor, MD, MSC
Associate Professor
Health Services Research
Breast Medical Oncology
The University of Texas MD Anderson Cancer Center



John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief, Hematology and Oncology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center



Edgardo S. Santos Castillero, M.D., FACP
Florida Precision Oncology, a Division of Genesis Care
Medical Director of Research Services
Thoracic and Head/Neck Cancer Programs
Clinical Affiliate Associate Professor
Charles E. Schmidt College of Medicine
Florida Atlantic University
Secretary, Florida Society of Clinical Oncology (FLASCO)
Florida



Sergio A. Giralt, MD
Deputy Head Division of Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York



**Taimur Sher, MD**Professor of Medicine
Consultant Hematology and Medical Oncology
Co-Chair Institutional Review Board
Medical Director Mortality Improvement
Florida





Saranya Chumsri, M.D. Associate Professor of Medicine Jacoby Center for Breast Health Mayo Clinic Cancer Center South Jacksonville. FL



Michael L. Nieder, MD
Professor of Oncologic Sciences,
University of South Florida Morsani College of Medicine
Medical Director, Blood and Marrow Transplant and
Cellular Immunotherapy, H. Lee Moffitt Cancer Center
Tampa, FL



Crystal S. Denlinger, MD FACP
Chief, Gastrointestinal Medical Oncology
Deputy Director, Phase 1 Program
Director, Survivorship Program
Associate Professor, Department of Hematology/Oncology
Philadelphia, PA



Eneida R. Nemecek, MD, MS, MBA
Nancy Jaggar Blount Endowed
Professor of Pediatrics & Medical Oncology
Medical Director of Clinical Research
Knight Cancer Institute
Oregon Health & Science University
Portland, OR



Carlos J. Pérez-López, MD
Infectious Diseases
Program Director Infectious Diseases TCT Oncology
BMT and Cellular Therapy Hospital Auxilio Mutuo
Department of Internal Medicine Hospital Auxilio Mutuo
Associated Professor Universidad Central del Caribe
San Juan, PR



**Sophie M. Lanzkron, MD, MHS**Professor in Medicine,
Department of Medicine (Hematology) and Oncology
Johns Hopkins University,
Baltimore, MD





Farhad Ravandi-Kashani, MD
Professor, Department of Leukemia,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center,
Houston, TX




**Harold J. Burstein, MD, PhD**Medical Oncologist at Dana-Farber Cancer Institute
Professor of Medicine at Harvard Medical School
Boston, MA



Guillermo García-Manero, M.D.

Professor, Department of Leukemia,
Chief, Section of Myelodysplastic Syndromes
Fellowship Program Director
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center,
Houston, TX



Luis E. Raez, MD, FACP, FCCP
Chief Scientific Officer & Medical Director
Memorial Cancer Institute
Director, Thoracic Oncology Program
Memorial Health Care System
Pembroke Pines, FL



Alison J. Moskowitz, MD
Associate Attending Physician Lymphoma Service
Hematologic Oncology Division
Department of Medicine
Memorial Hospital for Cancer & Allied Diseases
New York, NY



**Jesús San-Miguel, MD, PhD**Professor of Medicine-Hematology
Director of Clinical and Translational Medicine
University of Navarra
Spain





**Wendy Stock, MD, MA**Professor of Leukemia
University of Chicago Medicine
Chicago, IL



Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSMR
Co-Director, Cardiac Radiology Services,
Department of Diagnostic Radiology,
Division of Diagnostic Imaging,
Associate Professor, Department of Cardiology,
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center,
Houston, TX



**PAUL GRAHAM FISHER, MD, MHS**Division of Child Neurology
Department of Neurology and Neurological Sciences
Stanford University Medical Center
Palo Alto, CA



Melissa Alsina, MD Head, Myeloma BMT-CI Program H. Lee Moffitt Cancer Center Tampa, Florida



**Shayma Master Kazmi, M.D., R. Ph.**Director of Advanced Center of Thoracic Oncology
Medical Oncologist and Hematologist
New Jersey



**Raja Mudad, MD**Oncologist, Founding Partner
Florida Precision Oncology
Miami, Florida



## **PROGRAM**

## "OVERCOMING NEW CHALLENGES IN THE ONCOLOGY PRACTICE"

## FRIDAY PM MARCH 12, 2021

5:00 PM

5:30 - 8:00 PM

6:45 pm

**REGISTRATION** 

**Virtual Exhibits Opening** 

**Welcome Remarks** 

Dr. Sixto Pérez, MD President AHOMPR

7:00 - 7:30 PM

PROMOTIONAL SPEAKER PROGRAM

Topic:" Treatment Options for the Management of Certain Patients with

First Line Non-Small Cell Lung Cancer"

By: Raja Mudad, MD Sponsored by: BMS A Non-CME activity

#### SCIENTIFIC PROGRAM

Moderator: Dr. Alexis Cruz

7:30 - 8:00 PM

#### JENARO HADDOCK MEMORIAL LECTURE

Topic: "Update Treatment AML: Targeted Agents"

Dr. Farhad Rayandi

Professor, Department of Leukemia

The University of Texas MD Anderson Cancer Center

Houston, TX

8:00 PM

**OPENING ARTISTIC ACTIVITY** 

MANOLO MONGIL

## SATURDAY MARCH 13, 2021

7:30 AM 8:00 AM 8:30-9:00 AM

#### REGISTRATION

#### **VIRTUAL EXHIBITS OPENING**

### PROMOTIONAL SPEAKER PROGRAM

Topic:" Redefining Approaches in Early-Line Multiple Myeloma

Treatment (FASPRO™)"

By: Melissa Alsina, MD

Sponsored by: Janssen

A Non-CME activity

#### **SCIENTIFIC PROGRAM**

Moderator: Dr. Alexis Cruz

9:00-9:15 AM	WELCOME REMARKS  DR. SIXTO PEREZ - President AHOMPR
9:30-10:00 AM	Topic: "Next Generation Sequencing for patients with GI Cancer"
10.00 10.20 AM	Dr. John L. Marshall - Lombardi Comprehensive Cancer Center (Georgetown U.)
10:00-10:30 AM	Topic: "Immunotherapy in GI Cancer"  Dr. Crystal Denlinger - Fox Chase Cancer Center (Temple University)
10:30- 11:00 AM	DR. ENRIQUE VELEZ GARCIA MEMORIAL LECTURE
	Topic: "Early-stage Breast Cancer in the COVID19 Era"
	Dr. Harold Burstein
	Professor of Medicine, Harvard Medical School
	Dana-Farber Cancer Institute
	Boston, MA
11:00 – 11:30AM	Topic:" Amyloidosis Review"
	Dr. Taimur Sher - Mayo Clinic (Jacksonville, Florida)
11:30 – 12:30 PM	VIRTUAL EXHIBITS - BREAK
12:30-1:00PM	Topic: "Relapsed/Refractory Hodgkin Lymphoma"
	Dr. Alison J. Moskowitz - Memorial Sloan Kettering Cancer Center (NYC)
1:00-1:30PM	Topic: "New Options in Treatment for HER2+ Breast Cancer"

Dr. Mariana Chavez Mac Gregor - MD Anderson Cancer Center (Houston, TX)

1:30-2:00PM	Topic: "Immunotherapy in Breast Cancer"  Dr. Saranya Chumsri - Mayo Clinic (Jacksonville, Florida)
2:00 – 2:30 PM	VIRTUAL EXHIBITS - BREAK
2:30 PM	Hematology-Oncology Fellows Cases Presentation
	Virtual Pediatric Oncology Section
9:00 – 9:30 AM	Topic: "ALL in AYA Population"
	Dr. Wendy Stock - University of Chicago Medicine (Chicago, IL)
9:30- 10:00 AM	Topic: "Aplastic Anemia and BM Failure Syndromes"  Dr. Michael Nieder - Moffitt Cancer Center (Tampa, FL)
10:00- 10:30 AM	Topic: "5 Brain Tumors in Children and Young Adults that Every Oncologist Should Know"  Dr. Paul Graham Fisher - Stanford University (Palo Alto, CA)
5:00pm	Closing Artistic Activity Show: Hermes Croatto Raffle for Members Physicians AHOMPR
SUNDAY MARCH 14, 2021	
7:30 AM 8:00 AM	REGISTRATION VIRTUAL EXHIBITS OPENING
8:30-9:00 AM	PROMOTIONAL SPEAKER PROGRAM  Topic: "An Individualized Approach:  A CDK 4 & 6 Inhibitor for Women with Reduced Survival in HR+, HER2- MBC"  By: Dr. Shayma Master Kazmi

Sponsored by: LILLY A Non-CME activity

11:15 -12:30PM

9:15-9:45 AM	Topic: "Immunotherapy in Non-Metastatic Lung Cancer"
	Dr. Luis Raez - Memorial Cancer Institute (Hollywood, FL)
9:45-10:15 AM	Topic:" Mutation-Guided Therapy of Metastatic Lung Cancer:
	Current, New and Future Targets"
	Dr. Edgardo S. Santos - Florida Precision Oncology R&D (Boca Raton, FL)
10:15-10:45 AM	DR. ENRIQUE PÉREZ SANTIAGO MEMORIAL LECTURE
	Topic: "Update Treatment MDS: New Agents"
	Dr. Guillermo Garcia Manero
	Professor, Department of Leukemia
	Chief, Section of Myelodysplastic Syndromes, Department of Leukemia
	The University of Texas MD Anderson Cancer Center
	Houston, TX
10:45-11:15 AM	Topic: "Updates in Smoldering MM
	Dr. Jesus San Miguel - Clínica Universidad de Navarra (Pamplona, España)
12:30-1:00 PM	Topic: "CART: Basic concepts for the Community Oncologist"
	Dr. Sergio Giralt - Memorial Sloan Kettering Cancer Center (NYC)
1:30-2:00PM	Topic: "Cancer Patient Management during the COVID-19 Pandemic"
	Dr. Carlos Perez – TCT Oncology LLC, Hospital Auxilio Mutuo (San Juan, PR)
2:00- 2:30PM	Topic: "Cardio-Oncology Overview: Basic concepts for the Oncology specialist"
	Dr. Juan C. Lopez Mattei - MD Anderson Cancer Center (Houston, TX)
2:30 PM	VIRTUAL EXHIBITS - BREAK
	Virtual Pediatric Oncology Section
9:00 - 9:30AM	Topic: "Pediatric Soft Tissue and Bone Sarcomas"
	Dr. Paul A Meyers - Memorial Sloan Kettering Cancer Center (NYC)
9:30 -10:00AM	Topic: "Disease Modifying Therapy in Sickle Cell Disease"
	Dr. Sophie Miriam Lanzkron - The Johns Hopkins Hospital (Baltimore, MD)
10:00 - 10:30AM	Topic: "Pediatric BMT Review"
	Dr. Eneida Nemecek - Northwest Marrow Transplant Program (Portland, OR)

**VIRTUAL EXHIBITS - BREAK** 



# CONFERENCE REGISTRATION FORM ALL INFORMATION STATED ABOVE WILL REMAIN CONFIDENTIAL TO AHOMPR

umber Dept. / Suite  ate Zip Code  SISTRATION RATES  Cash / Check	_ Fax:
istration rates	_
SISTRATION RATES	_
SISTRATION RATES	_
SISTRATION RATES	_
	<b>S</b>
Cash / Check	Ore dit Card
-	Credit Card
e members of the association	on and who have their
FREE	FREE
npanied by a letter from you	ur director/chair
101000	\$270,00
\$260.00	\$270,00
\$260.00  ARTICIPATE IN THE CONFERENCES	\$270,00
ARTICIPATE IN THE CONFERENCES	\$270.00
	FREE

Cancellation Policy: In case of no show, one night stay penalty will be applied. Cancellations will be accepted with no penalty up to 72 hours prior to arrival. Penalty will be your responsibility

PLEASE TYPE OR PRINT



For more information: **Germaine Quiñones** 

Medical Licence #

Meeting Coordinator Tel: 787-608-1477 Fax: 787-841-6886

e-Mail: ahomprga@gmail.com